Assessing Blackbaud (BLKB) Valuation After Prolonged Share Price Weakness

Advertisement

Key recent performance snapshot

Blackbaud (BLKB) has drawn investor attention after recent trading, with the share price at $54.87 and returns showing a 0.3% move over the past day and a small decline over the past week.

The stock has recorded deeper negative returns over the past month, past 3 months, year to date, and past year. This may prompt some investors to reassess how its current valuation lines up with the company’s underlying business profile.

See our latest analysis for Blackbaud.

That recent 14.7% 1 month share price decline, along with a 28.5% 1 year total shareholder return loss, suggests momentum has been fading and investors are reassessing Blackbaud’s risk and growth profile at around $54.87.

If Blackbaud’s recent swings have you reconsidering where you look for opportunities, this can be a good moment to broaden your search with fast growing stocks with high insider ownership.

So, with Blackbaud trading at $54.87, carrying an intrinsic discount of about 45% and a 39% gap to the current analyst price target, is there mispricing here, or is the market already factoring in its future growth?

Most Popular Narrative: 26.3% Undervalued

At $54.87, Blackbaud sits well below the most followed fair value estimate of $74.50, which is built on a detailed long term earnings and margin path.

The shift toward cloud-based SaaS subscription models and improvements in operational efficiency, including automation and AI-driven internal initiatives, are lowering costs and improving gross and net margins, providing significant leverage to long-term earnings growth.

Read the complete narrative.

Want to see what this margin story really assumes? The narrative leans on steady revenue gains, a sharp earnings swing, and a future earnings multiple that has to hold. The exact mix of growth, profitability, and discount rate might surprise you.

Result: Fair Value of $74.50 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this story can be challenged if competition compresses pricing and margins, or if tighter nonprofit budgets slow tech spending and weaken recurring revenue trends.

Find out about the key risks to this Blackbaud narrative.

Build Your Own Blackbaud Narrative

If you see the story differently or prefer to work from your own assumptions and checks, you can build a custom view in just a few minutes with Do it your way.

A great starting point for your Blackbaud research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.

Looking for more investment ideas?

If Blackbaud has your attention, do not stop there. You can quickly size up fresh ideas using targeted stock screens tailored to what matters most to you.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Valuation is complex, but we're here to simplify it.

Discover if Blackbaud might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

MI
mitchell_lawler
mitchell_lawler

Moderna nearly tripled overnight, and every other mRNA stock jumped with it. I think that could be a trap.

Moderna nearly tripled overnight, and every other mRNA stock jumped with it. I think that could be a trap. cover
138
PR
pri_dlp7z

Happy for the melanoma patients. It is no surprise that other companies moved up too. It's the optionality getting priced in.

QU
Quantanium

There’s a 60% to 85% probability of the vaccine being approved based on historical drug development data. Could be a lot of scrutiny by the FDA due to the novel platform used.

Market might be getting a little ahead of itself here.

About NasdaqGS:BLKB

Blackbaud

Engages in the providing AI-powered solutions in the United States and internationally.

Undervalued with acceptable track record.

Advertisement

Weekly Picks

RI
Rick_Orford
FJET logo
Rick_Orford on Starfighters Space ·

The 1960s Fighter Jet That Could Crack Open a $20 Billion Satellite Market

Fair Value:US$520.6% undervalued
54 users have followed this narrative
2 users have commented on this narrative
7 users have liked this narrative
JO
John_Eric
MELI logo
John_Eric on MercadoLibre ·

MercadoLibre and the Spreadsheet Trick That Decides Everything

Fair Value:US$7.31k73.9% undervalued
99 users have followed this narrative
2 users have commented on this narrative
15 users have liked this narrative
RC
PYPL logo
rcb9 on PayPal Holdings ·

Ten Percent More Volume, One Percent More Transaction Margin

Fair Value:US$70.8913.6% undervalued
13 users have followed this narrative
1 users have commented on this narrative
6 users have liked this narrative
HE
HedgeY
MU logo
HedgeY on Micron Technology ·

Micron - The Memory Bottleneck Behind the AI Supercycle

Fair Value:US$1.25k25.0% undervalued
38 users have followed this narrative
0 users have commented on this narrative
12 users have liked this narrative

Updated Narratives

DA
AIIO logo
david_1211213 on Robo.ai ·

Robo.ai (AIIO): A Long-Term Bullish Technical Setup

Fair Value:US$5.6449.8% undervalued
1 users have followed this narrative
7 users have commented on this narrative
1 users have liked this narrative
RO
RockeTeller
WRLG logo
RockeTeller on West Red Lake Gold Mines ·

This Junior Gold Mine Just Hit Commercial Production, 120k oz Roadmap at $7,000 Gold

Fair Value:CA$4.3681.4% undervalued
27 users have followed this narrative
8 users have commented on this narrative
0 users have liked this narrative
AS
AstrisCorporateAdvisory
9436 logo
AstrisCorporateAdvisory on Okinawa Cellular Telephone ·

Mobile strategy pays off as churn falls

Fair Value:JP¥3.26k23.3% overvalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28022.3% undervalued
331 users have followed this narrative
9 users have commented on this narrative
16 users have liked this narrative
CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.9115.3% overvalued
184 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative
KI
AMZN logo
KiwiInvest on Amazon.com ·

Amazon's high growth, high tech segments propel its profits, while traditional segments plod along

Fair Value:US$475.0944.0% undervalued
209 users have followed this narrative
1 users have commented on this narrative
8 users have liked this narrative